Compare Extra Space Storage, Inc. (EXR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Extra Space Storage, Inc. trades at $146.41 (market cap $30.98B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.7× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| EXR | REGN | |
|---|---|---|
Market Cap | $30.98B | $83.19B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $812.27 |
52-Week Low | $126.67 | $555.51 |
Enterprise Value | $44.70B | $77.90B |
Dividend Yield | 4.42% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $149.54, near its 52-week high, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 core FFO of $2.15 per share, exceeding estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 27.79% in 2025, though valuation ratios like P/E of 33.01 suggest a premium pricing.
Outlook is positive with analyst consensus price target of $157.25, but risks include high debt levels and competitive pressures in the self-storage sector. The stock offers a dividend yield supported by solid cash flows, making it attractive for income-focused investors amid cautious market sentiment.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
